Neuroone Medical Technologies Corp (NMTC) - Total Assets
Based on the latest financial reports, Neuroone Medical Technologies Corp (NMTC) holds total assets worth $7.86 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Neuroone Medical Technologies Corp (NMTC) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Neuroone Medical Technologies Corp - Total Assets Trend (2010–2025)
This chart illustrates how Neuroone Medical Technologies Corp's total assets have evolved over time, based on quarterly financial data. See Neuroone Medical Technologies Corp shareholders equity for net asset value and shareholders' equity analysis.
Neuroone Medical Technologies Corp - Asset Composition Analysis
Current Asset Composition (September 2025)
Neuroone Medical Technologies Corp's total assets of $7.86 Million consist of 94.8% current assets and 5.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.9% |
| Accounts Receivable | $1.26 Million | 11.7% |
| Inventory | $2.23 Million | 20.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $44.95K | 0.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Neuroone Medical Technologies Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NMTC company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuroone Medical Technologies Corp's current assets represent 94.8% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 60.9% of total assets in 2025, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 20.7% of total assets.
Neuroone Medical Technologies Corp Competitors by Total Assets
Key competitors of Neuroone Medical Technologies Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Neuroone Medical Technologies Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.37 | 2.13 | 12.41 |
| Quick Ratio | 3.26 | 1.09 | 12.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.69 Million | $1.99 Million | $8.52 Million |
Neuroone Medical Technologies Corp - Advanced Valuation Insights
This section examines the relationship between Neuroone Medical Technologies Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.76 |
| Latest Market Cap to Assets Ratio | 1.35 |
| Asset Growth Rate (YoY) | 100.9% |
| Total Assets | $10.79 Million |
| Market Capitalization | $14.57 Million USD |
Valuation Analysis
Above Book Valuation: The market values Neuroone Medical Technologies Corp's assets above their book value (1.35x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Neuroone Medical Technologies Corp's assets grew by 100.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuroone Medical Technologies Corp (2010–2025)
The table below shows the annual total assets of Neuroone Medical Technologies Corp from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $10.79 Million | +100.85% |
| 2024-09-30 | $5.37 Million | -33.68% |
| 2023-09-30 | $8.10 Million | -36.85% |
| 2022-09-30 | $12.82 Million | +61.52% |
| 2021-09-30 | $7.94 Million | +66.78% |
| 2020-09-30 | $4.76 Million | +793.66% |
| 2019-09-30 | $532.62K | +143.52% |
| 2018-09-30 | $218.72K | -71.10% |
| 2017-09-30 | $756.93K | +41082.26% |
| 2016-09-30 | $1.84K | +796.59% |
| 2015-09-30 | $205.00 | -66.28% |
| 2014-09-30 | $608.00 | -45.62% |
| 2013-09-30 | $1.12K | 0.00% |
| 2012-09-30 | $1.12K | -91.93% |
| 2011-09-30 | $13.85K | +51.73% |
| 2010-09-30 | $9.13K | -- |
About Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson'… Read more